Decipher Labs Limited

BSE:524752 Stock Report

Market Cap: ₹159.8m

Decipher Labs Valuation

Is 524752 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 524752 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 524752 (₹15.82) is trading below our estimate of fair value (₹96.54)

Significantly Below Fair Value: 524752 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 524752?

Other financial metrics that can be useful for relative valuation.

524752 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.2x
Enterprise Value/EBITDA5.7x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 524752's PE Ratio compare to its peers?

The above table shows the PE ratio for 524752 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37.9x
543500 Evoq Remedies
43.2xn/a₹195.5m
531210 Colinz Laboratories
33.8xn/a₹170.0m
542678 Cian Healthcare
43.2xn/a₹109.7m
524400 Ishita Drugs and Industries
31.2xn/a₹237.0m
524752 Decipher Labs
72.9xn/a₹159.8m

Price-To-Earnings vs Peers: 524752 is expensive based on its Price-To-Earnings Ratio (72.9x) compared to the peer average (37.9x).


Price to Earnings Ratio vs Industry

How does 524752's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.4%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.4%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 524752 is expensive based on its Price-To-Earnings Ratio (72.9x) compared to the Indian Pharmaceuticals industry average (38.3x).


Price to Earnings Ratio vs Fair Ratio

What is 524752's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

524752 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio72.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 524752's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies